CLINICAL RESEARCH: METABOLIC SYNDROME
Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis
Kaisa M. Mäki-Petäjä, BSc*,1,*,
Anthony D. Booth, MD, MRCP2,*,
Frances C. Hall, DPhil, FRCP ,3,
Sharon M.L. Wallace, BA, RN*,
John Brown, DM, FRCP ,
Carmel M. McEniery, PhD* and
Ian B. Wilkinson, DM, FRCP2,*
* Clinical Pharmacology Unit, University of Cambridge, Cambridge, United Kingdom
Department of Clinical Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
Trinity College, University of Cambridge, Cambridge, United Kingdom.
Manuscript received February 6, 2007;
revised manuscript received April 20, 2007,
accepted April 22, 2007.
* Reprint requests and correspondence: Kaisa Mäki-Petäjä, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke’s Hospital, BOX 110, Cambridge CB2 0QQ, United Kingdom. (Email: km391{at}cam.ac.uk).
Objectives: The aim of this study was to investigate the effect of simvastatin and ezetimibe on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in a cohort of rheumatoid arthritis (RA) patients.
Background: Rheumatoid arthritis is a chronic inflammatory condition associated with increased cardiovascular risk. Statins reduce inflammation and disease activity in RA patients, but whether this is due to pleiotropism or cholesterol lowering per se is unclear.
Methods: Twenty patients received 20 mg simvastatin or 10 mg ezetimibe each for 6 weeks in a randomized double-blind crossover study. Disease activity, blood pressure, aortic pulse wave velocity (PWV), brachial artery flow-mediated dilation (FMD), and serum inflammatory markers were measured before and after each treatment.
Results: Both ezetimibe and simvastatin significantly reduced total cholesterol (–0.62 ± 0.55 mmol/l and –1.28 ± 0.49 mmol/l, respectively; p < 0.001), low-density lipoprotein cholesterol (–0.55 ± 0.55 mmol/l and –1.28 ± 0.49 mmol/l; p < 0.0001), and C-reactive protein (–5.35 ± 9.25 mg/l and –5.05 ± 6.30 mg/l; p < 0.001). Concomitantly, Disease Activity Score (–0.55 ± 1.01 and –0.67 ± 0.91; p = 0.002), aortic PWV (–0.69 ± 1.15 m/s and –0.71 ± 0.71 m/s; p = 0.001), and FMD (1.37 ± 1.17% and 2.51 ± 2.13%; p = 0.001) were significantly improved by both drugs.
Conclusions: This study demonstrates that both ezetimibe and simvastatin reduce disease activity and inflammatory markers to a similar extent in patients with RA. Therapy is also associated with a concomitant reduction in aortic PWV and improvement in endothelial function. This suggests that cholesterol lowering per se has anti-inflammatory effects and improves vascular function in RA.
|
Abbreviations and Acronyms
| | AIx = augmentation index | | CRP = C-reactive protein | | DAS = Disease Activity Score | | ESR = erythrocyte sedimentation rate | | FMD = flow-mediated dilatation | | GTN = glyceryl trinitrate | | oxLDL = oxidized low-density lipoprotein | | PWV = pulse wave velocity | | RA = rheumatoid arthritis |
|
This article has been cited by other articles:
|
|
|
|
 
M J L Peters, D P M Symmons, D McCarey, B A C Dijkmans, P Nicola, T K Kvien, I B McInnes, H Haentzschel, M A Gonzalez-Gay, S Provan, et al.
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Ann Rheum Dis,
February 1, 2010;
69(2):
325 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Angel, S. A. Provan, H. L. Gulseth, P. Mowinckel, T. K. Kvien, and D. Atar
Tumor Necrosis Factor-{alpha} Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies: A Controlled Study
Hypertension,
February 1, 2010;
55(2):
333 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sluijs, Y. Plantinga, B. de Roos, L. I Mennen, and M. L Bots
Dietary supplementation with cis-9,trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults
Am. J. Clinical Nutrition,
January 1, 2010;
91(1):
175 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bass, A. L Hinderliter, and C. R Lee
The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk
Ann. Pharmacother.,
December 1, 2009;
43(12):
2021 - 2030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Crilly, V. Kumar, H. J. Clark, N. W. Scott, A. G. MacDonald, and D. J. Williams
Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors
Rheumatology,
December 1, 2009;
48(12):
1606 - 1612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Helmers, D. C. Gowda, K. C. Kain, and W. C. Liles
Statins Fail to Improve Outcome in Experimental Cerebral Malaria and Potentiate Toll-Like Receptor-Mediated Cytokine Production by Murine Macrophages
Am J Trop Med Hyg,
October 1, 2009;
81(4):
631 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Burghuber and A. Valipour
Knowing Chronic Obstructive Pulmonary Disease by Heart: Cumulating Evidence of Systemic Vascular Dysfunction
Am. J. Respir. Crit. Care Med.,
September 15, 2009;
180(6):
487 - 488.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Tershakovec, E. P. Veltri, and R. C. Pasternak
Letter by Tershakovec et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation"
Circulation,
September 1, 2009;
120(9):
e67 - e67.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Settergren, L. Ryden, and J. Pernow
Letter by Settergren et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation"
Circulation,
September 1, 2009;
120(9):
e68 - e68.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Recio-Mayoral, J. C. Mason, J. C. Kaski, M. B. Rubens, O. A. Harari, and P. G. Camici
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease
Eur. Heart J.,
August 1, 2009;
30(15):
1837 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Kuhl
Hypertrophic cardiomyopathy, fibrosis, and aortic stiffness an unidentified association unraveled by magnetic resonance imaging.
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
263 - 264.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Semb, S. Provan, T. Kvien, and T. Pedersen
Effect of high-intensity statin treatment in rheumatoid arthritis: a case with possible coronary atheroma regression and progression of rheumatoid valve degeneration
BMJ Case Reports,
June 21, 2009;
2009(jun21_1):
bcr0820080717 - bcr0820080717.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. J. Al Badarin, I. J. Kullo, S. L. Kopecky, and R. J. Thomas
Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?
Mayo Clin. Proc.,
April 1, 2009;
84(4):
353 - 361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Montecucco, F. Burger, G. Pelli, N. K. Poku, C. Berlier, S. Steffens, and F. Mach
Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes
Rheumatology,
March 1, 2009;
48(3):
233 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Bruce
Recent Developments in the Treatment of Rheumatoid Arthritis
Journal of Pharmacy Practice,
February 1, 2009;
22(1):
65 - 74.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas
Hypertension in rheumatoid arthritis
Rheumatology,
September 1, 2008;
47(9):
1286 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kinlay
Vascular form and function: two mechanisms for cardiovascular prevention
Eur. Heart J.,
July 2, 2008;
29(14):
1711 - 1713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. TAYLOR
Given the ENHANCE trial results, ezetimibe is still unproven
Cleveland Clinic Journal of Medicine,
July 1, 2008;
75(7):
497 - 506.
[Full Text]
[PDF]
|
|
|
|
